Could a simple Vitamin-Like injection slash anemia drug doses for dialysis patients?

NCT ID NCT07160452

Not yet recruiting Disease control Sponsor: Shaikh Zayed Hospital, Lahore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether adding levocarnitine injections to standard care can lower the amount of anemia medication needed by people on hemodialysis. About 94 adults with kidney failure and anemia will receive either levocarnitine after each dialysis session or usual care alone for six months. The goal is to see if levocarnitine helps maintain healthy red blood cell levels with fewer drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Levocarnitine (a form of carnitine) given as an injection after dialysis
What this could lead to: If it works, this could mean people on dialysis need lower doses of anemia drugs, which may reduce side effects and treatment costs.
What could go wrong: This is a small, early-phase trial with only 94 participants, so results may not apply to everyone. It is also possible that levocarnitine does not significantly lower drug needs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia anemia due to chronic disorder chronic kidney disease end stage renal failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA END-STAGE RENAL DISEASE KIDNEY FAILURE RENAL DIALYSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.